11 March 2019

Amedeo Smart

Independent Medical Education

Subscriber: th..@boehringer-ingelheim.com

HIV Infection

11 March 2019 | n=42

  1. Flick RJ, Simon KR, Nyirenda R, Namachapa K, et al.
    The HIV diagnostic assistant-early findings from a novel HIV testing cadre in Malawi.
    AIDS 2019.

  2. Honge BL, Petersen MS, Jespersen S, Medina C, et al.
    T and B-cell perturbations identify distinct differences in HIV-2 compared with HIV-1 induced immunodeficiency.
    AIDS 2019.

  3. Honge BL, Petersen MS, Jespersen S, Medina C, et al.
    T and B-cell perturbations are similar in ART-naive HIV-1 and HIV-1/2 dually infected patients.
    AIDS 2019.

  4. Corma-Gomez A, Morano Amado L, Tellez F, Rivero-Juarez A, et al.
    HIV infection does not impact on the risk of liver complications in HCV-infected patient with advanced fibrosis, after sustained virological response with DAA.
    AIDS 2019.

  5. Zhang WR, Scherzer R, Estrella MM, Ascher SB, et al.
    Tenofovir disoproxil fumarate initiation and changes in urinary biomarker concentrations among HIV-infected men and women.
    AIDS 2019;33:723-733.

  6. Garrido C, Tolstrup M, Sogaard OS, Rasmussen TA, et al.
    In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.
    AIDS 2019;33:605-613.

  7. .
    Impact of aging and HIV infection on serologic response to seasonal influenza vaccination: Erratum.
    AIDS 2019;33:771.

  8. .
    Assessment of sarcopenia in virally suppressed HIV-infected Asians receiving treatment: Erratum.
    AIDS 2019;33:769.

  9. .
    Impact of glycemic status on longitudinal cognitive performance in men with and without HIV infection: Erratum.
    AIDS 2019;33:767.

  10. Duss FR, Moulin K, Moret Bochatay M, Bally F, et al.
    Pneumococcal meningitis without pleocytosis in a patient infected with HIV-1.
    AIDS 2019;33:765-766.

  11. Ahmad A, Samarani S, Kumar V.
    Lipopolysaccharide-acylating capacity of the gut microbiota and its potential impact on the immunopathogenesis of HIV infection.
    AIDS 2019;33:753-755.

  12. .
    Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1.
    AIDS 2019;33:745-751.

  13. Berenguer J, Gil-Martin A, Jarrin I, Montes ML, et al.
    Reinfection by hepatitis C virus following effective all-oral direct-acting antiviral drug therapy in HIV/hepatitis C virus coinfected individuals.
    AIDS 2019;33:685-689.

  14. Ling L, Wu T, To KKW, Cheung KW, et al.
    Vedolizumab-mediated integrin alpha4beta7 blockade does not control HIV-1SF162 rebound after combination antiretroviral therapy interruption in humanized mice.
    AIDS 2019;33:F1-F12.

  15. Furler RL, Nixon DF.
    The Intimate Relationship Between CD4+ T Cell Morphology and HIV-1 Infection.
    AIDS Res Hum Retroviruses 2019.

  16. Summers N, Kelley C, Armstrong W, Marconi V, et al.
    Not a Disease of the Past: A Case-Series of Progressive Multifocal Leukoencephalopathy in the Established Antiretroviral Era.
    AIDS Res Hum Retroviruses 2019.

  17. Abela IA, Scherrer AU, Boni J, Yerly S, et al.
    Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients.
    Clin Infect Dis 2019.

  18. Prabhu S, McFall AM, Mehta SH, Srikrishnan AK, et al.
    Psychosocial barriers to viral suppression in a community-based sample of HIV-positive men who have sex with men and people who inject drugs in India.
    Clin Infect Dis 2019.

  19. Yindom LM, Simms V, Majonga ED, McHugh G, et al.
    Unexpectedly High Prevalence of Cytomegalovirus DNAemia in Older Children and Adolescents With Perinatally Acquired Human Immunodeficiency Virus Infection.
    Clin Infect Dis 2019.

  20. Katz I, Jha AK.
    HIV in the United States: Getting to Zero Transmissions by 2030.
    JAMA 2019.

  21. Jao J, Jacobson DL, Yu W, Borkowsky W, et al.
    A comparison of metabolic outcomes between obese HIV-exposed uninfected youth from the PHACS SMARTT Study and HIV-unexposed youth from the NHANES Study in the U.S.
    J Acquir Immune Defic Syndr 2019.

  22. Liu Y, Silenzio VMB, Nash R, Luther P, et al.
    Suboptimal recent and regular HIV testing among Black men who have sex with men in the United States: Implications from a meta-analysis.
    J Acquir Immune Defic Syndr 2019.

  23. van der Straten A, Browne EN, Shapley-Quinn MK, Brown ER, et al.
    First Impressions Matter: How Initial Worries Influence Adherence to the Dapivirine Vaginal Ring.
    J Acquir Immune Defic Syndr 2019.

  24. Slogrove AL, Powis KM, Zash R.
    Methodological considerations in evaluating pregnancy outcomes in women living with HIV.
    J Acquir Immune Defic Syndr 2019.

  25. Zhang Y, Barnighausen T, Eyal N.
    When Global ART Budgets Cannot Cover All Patients, Who Should Be Eligible?
    J Acquir Immune Defic Syndr 2019.

  26. Mimiaga MJ, Hughto JMW, Biello KB, Santostefano CM, et al.
    Longitudinal analysis of syndemic psychosocial problems predicting HIV risk behavior among a multicity prospective cohort of sexually active young transgender women in the United States.
    J Acquir Immune Defic Syndr 2019.

  27. Hoover KW, Hu X, Porter SE, Buchacz K, et al.
    HIV diagnoses and the HIV care continuum among women and girls aged >/=13 years - 39 states and the District of Columbia, 2015-2016.
    J Acquir Immune Defic Syndr 2019.

  28. Huiting ED, Gittens K, Justement JS, Shi V, et al.
    Impact of treatment interruption on HIV reservoirs and lymphocyte subsets in individuals who had initiated antiretroviral therapy during the early phase of infection.
    J Infect Dis 2019.

  29. Kusejko K, Bachmann N, Chaudron SE, Nguyen H, et al.
    A systematic phylogenetic approach to study the interaction of HIV-1 with coinfections, non-communicable and opportunistic diseases.
    J Infect Dis 2019.

  30. Carlisle LA, Turk T, Kusejko K, Metzner KJ, et al.
    Viral diversity from next-generation sequencing of HIV-1 samples provides precise estimates of infection recency and time since infection.
    J Infect Dis 2019.

  31. Mayaphi SH, Martin DJ, Quinn TC, Stoltz AC, et al.
    Field Performance of the INSTI HIV-1/-2 Antibody Test in Two South African Antenatal Clinics.
    J Med Virol 2019.

  32. Wei X, Zhang Y, Santella AJ, Wang L, et al.
    Effect of early highly active antiretroviral therapy on viral suppression among newly diagnosed men who have sex with men living with HIV in Xi'an, China.
    J Med Virol 2019.

  33. Llewellyn GN, Seclen E, Wietgrefe S, Liu S, et al.
    A humanized mouse model of HIV-1 latency with enrichment of latent virus in PD-1+ and TIGIT+ CD4 T cells.
    J Virol 2019.

  34. Li X, Huang L, Xiao Y, Yao X, et al.
    Development of an ORF45-derived peptide to inhibit the sustained RSK activation and lytic replication of Kaposi's sarcoma-associated herpesvirus.
    J Virol 2019.

  35. Pollara J, Jones DI, Huffman T, Edwards RW, et al.
    Bridging vaccine-induced HIV-1 neutralizing and effector antibody responses in rabbit and rhesus macaque animal models.
    J Virol 2019.

  36. Lee WS, Prevost J, Richard J, van der Sluis RM, et al.
    CD4- and time-dependent susceptibility of HIV-1-infected cells to ADCC.
    J Virol 2019.

  37. Mabvakure BM, Lambson BE, Ramdayal K, Masson L, et al.
    Evidence for both intermittent and persistent compartmentalization of HIV-1 in the female genital tract.
    J Virol 2019.

  38. Silver ZA, Dickinson GM, Seaman MS, Desrosiers RC, et al.
    A highly unusual V1 region of Env in an elite controller of HIV infection.
    J Virol 2019.

  39. Matchett WE, Anguiano-Zarate SS, Nehete PN, Shelton K, et al.
    Divergent HIV-1 Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques.
    J Virol 2019.

  40. Jaffe S.
    USA sets goal to end the HIV epidemic in a decade.
    Lancet 2019;393:625-626.

  41. Cohen J.
    Has a second person with HIV been cured?
    Science 2019;363:1021.

  42. Pike H.
    HIV-1 remission achieved in second patient, report UK researchers.
    BMJ 2019;364:l1019.

Display articles in

Amedeo HIV Infection

Data Origin

You selected the following journals for your Amedeo HIV Infection newsletter:

AIDS, AIDS Res Hum Retroviruses, Ann Intern Med, BMJ, Clin Infect Dis, J Acquir Immune Defic Syndr, J Clin Immunol, J Clin Invest, J Infect Dis, J Med Virol, J Virol, JAMA, Lancet, N Engl J Med, Nat Med, Pediatr Infect Dis J, Science, Virology.

To modify the journal selection, please open your Newsletter Management Page. If you don't remember the URL, please submit the email address of your Amedeo subscription.

Your email:

Amedeo HIV Infection

Five-Week Literature

10 June 2019

03 June 2019

27 May 2019

20 May 2019

13 May 2019

11 March 2019

Multidisciplinary Journal Club

  1. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, et al.
    Low-Dose Methotrexate for the Prevention of Atherosclerotic Events.
    N Engl J Med. 2019;380:752-762.

  2. O'Riordan W, Green S, Overcash JS, Puljiz I, et al.
    Omadacycline for Acute Bacterial Skin and Skin-Structure Infections.
    N Engl J Med. 2019;380:528-538.

  3. Flinn IW, van der Jagt R, Kahl B, Wood P, et al.
    First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
    J Clin Oncol. 2019 Feb 27:JCO1800605. doi: 10.1200/JCO.18.00605.

Every week, Amedeo's Multidisciplinary Journal Club (MJC) presents a selection of outstanding articles. Take a look beyond the horizon.

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016